Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0252W HIGH $1.91
Volume
243.95 K
Value Traded
162.00 K
Short % Float
4.28%
-11.26%Week
+15.53%1 Month
+28.1%3 Month
+20.34%6 Month
-96.49%5 Year
-96.4%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
84.73 M
EPS (TTM)
-1.41
P/E Ratio
-
Ent. Value
5.30 M
Total Shares
53.46 M
Float Shares
68.15 M
Insiders
9.75%
Institutions
41.94%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PMVP Catalyst Timeline
Dated clinical, regulatory and corporate events for PMV Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for PMV Pharmaceuticals, Inc.
166Total events
6Upcoming
20Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Equity OfferingCorporate
PMV Pharma commences underwritten public offering of common stock and warrants
▲Interim AnalysisrezatapoptTrial
Updated interim ovarian cancer data from PYNNACLE Phase 2 pivotal trial
platinum-resistant/refractory ovarian cancersource ↗
▲Enrollment CompleterezatapoptTrial
Enrollment completed for primary analysis in ovarian cancer cohort
platinum-resistant/refractory ovarian cancersource ↗
▲FDA Feedback ReceivedrezatapoptFDA Meeting
FDA feedback supports NDA submission strategy
platinum-resistant/refractory ovarian cancersource ↗
▲Enrollment CompleterezatapoptTrial
Enrollment completed for primary analysis in Phase 2 monotherapy portion of PYNNACLE
platinum-resistant/refractory ovarian cancersource ↗
◆Management ChangeCorporate
Laurie Stelzer appointed Chair of the Board, succeeding Rich Heyman
▲Orphan Drug DesignationrezatapoptDesignation
Rezatapopt granted Orphan Drug Designation by FDA for TP53 Y220C positive ovarian cancer
TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancersource ↗
▲PublicationrezatapoptPresentation
Phase 1 results of rezatapopt published in New England Journal of Medicine
TP53 Y220C-mutated advanced solid tumorssource ↗
▲Oral PresentationrezatapoptPresentation
Updated Phase 2 PYNNACLE results presented at SGO Annual Meeting
platinum-resistant/refractory ovarian cancer with TP53 Y220C mutationsource ↗
◆Enrollment UpdaterezatapoptTrial
Enrollment on track in Phase 2 pivotal portion of PYNNACLE trial
platinum-resistant/refractory ovarian cancer with TP53 Y220C mutationsource ↗
▲Orphan Drug DesignationrezatapoptDesignation
FDA granted Orphan Drug Designation to rezatapopt for TP53 Y220C positive ovarian cancer
TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancersource ↗
▲PublicationrezatapoptPresentation
Phase 1 results of rezatapopt published in New England Journal of Medicine
advanced solid tumors with TP53Y220C mutationsource ↗
▲Oral PresentationrezatapoptPresentation
New findings from PYNNACLE Phase 2 presented at 2026 ESGO Congress
TP53 Y220C positive ovarian cancersource ↗
●Enrollment MilestonerezatapoptTrial
Plan to enroll additional 20-25 platinum resistant/refractory ovarian cancer patients
platinum resistant/refractory ovarian cancersource ↗
●Enrollment CompleterezatapoptTrial
Expected completion of enrollment in Phase 2 portion of PYNNACLE study
advanced solid tumors with TP53 Y220C mutationsource ↗
▲Runway Guidance UpdateCorporate
Cash runway extended to end of 2026 after workforce reduction
◆Poster PresentationrezatapoptPresentation
Natural history and prognostic value of TP53 Y220C mutation in advanced solid tumors: A real-world study
advanced solid tumors with TP53 Y220C mutationsource ↗
◆Poster PresentationrezatapoptPresentation
Initial analysis of the pivotal PYNNACLE Phase 2 trial (poster)
locally advanced or metastatic solid tumors with a TP53 Y220C mutationsource ↗
▲Oral PresentationrezatapoptPresentation
Updated interim Phase 2 results presented at a conference
advanced solid tumors with TP53Y220C mutationsource ↗
▲Interim AnalysisrezatapoptTrial
Interim data from Phase 2 PYNNACLE trial of rezatapopt monotherapy
advanced solid tumors with TP53 Y220C mutationsource ↗
●Oral PresentationrezatapoptPresentation
Investor webinar to review Phase 2 interim data and regulatory update
advanced solid tumors with TP53 Y220C mutationsource ↗
▲FDA Feedback ReceivedrezatapoptFDA Meeting
FDA feedback on initial NDA submission strategy for platinum resistant/refractory ovarian cancer
platinum resistant/refractory ovarian cancersource ↗
▲Enrollment UpdaterezatapoptTrial
Enrollment on track in Phase 2 pivotal portion of PYNNACLE trial
TP53 Y220C and KRAS wild-type advanced solid tumorssource ↗
◆Interim AnalysisrezatapoptTrial
Interim analysis expected by mid-2025
TP53 Y220C and KRAS wild-type advanced solid tumorssource ↗
▲Enrollment UpdaterezatapoptTrial
Enrollment on track in Phase 2 pivotal portion of PYNNACLE trial; more than 90% of sites activated
TP53 Y220C and KRAS wild-type advanced solid tumorssource ↗
▲First Patient DosedrezatapoptTrial
Enrollment commenced in MD Anderson investigator-initiated Phase 1b study of rezatapopt monotherapy and in combination with azacitidine
relapsed or refractory AML/MDS harboring TP53 Y220C mutationsource ↗
▲FDA Feedback ReceivedrezatapoptFDA Meeting
FDA feedback on NDA submission strategy for PROC indication
platinum-resistant or refractory ovarian cancersource ↗
▲PublicationrezatapoptPresentation
Phase 1 results published in New England Journal of Medicine
TP53 Y220C-mutated tumorssource ↗
▲Oral PresentationrezatapoptPresentation
Updated Phase 2 data presented at 2025 AACR-NCI-EORTC conference
TP53 Y220C advanced solid tumorssource ↗
▲Trial InitiationrezatapoptTrial
Investigator-initiated Phase 1b study planned with MDACC and MSK; enrollment to begin Q1 2025
Recurrent or refractory AML/MDS with TP53 Y220C mutationsource ↗
▲Enrollment UpdaterezatapoptTrial
Enrollment on track in Phase 2 monotherapy portion of PYNNACLE trial
TP53 Y220C and KRAS wild-type advanced solid tumorssource ↗
▼Trial DiscontinuedrezatapoptTrial
Discontinued enrollment in Phase 1b combination arm with pembrolizumab due to limited clinical benefit
advanced solid tumors with TP53 Y220C mutationsource ↗
▲Enrollment UpdaterezatapoptTrial
Enrollment on track in Phase 2 monotherapy portion; >75% sites activated
TP53 Y220C and KRAS wild-type advanced solid tumorssource ↗
▼Trial DiscontinuedrezatapoptTrial
Discontinued enrollment in Phase 1b combination arm with pembrolizumab due to limited clinical benefit
TP53 Y220C advanced solid tumorssource ↗
●Poster PresentationrezatapoptPresentation
Rezatapopt food effect data presented at ACCP Annual Conference
TP53 Y220C advanced solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How PMVP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-09-10 | Rezatapopt (PC14586) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$15M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.2x
rNPV / MCap
Top 69%
Micro Cap(rank 454 of 658)
Percentile Rank
PMV Pharmaceuticals, Inc. faces pipeline headwinds (30/100), with $296M risk-adjusted pipeline value, led by rezatapopt in Advanced Solid Tumor (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| rezatapopt Small moleculeNCT04585750 | Advanced Solid Tumor | Phase 1 | RECRUITING | 300 | Dec 31, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every PMVP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| rezatapopt Fast TrackOrphan | platinum-resistant/refractory ovarian cancer | Phase 2 | 2026-08-31 | overall response rate: 46%; median duration of response: 10.0 months; patients evaluable: 76; complete responses: 4; partial responses: 29; unconfirmed partial responses: 2; median time to response: 1.3 months; discontinuation due to AEs: 5%Read More | PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal TrialRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Carulli MichaelOfficer (Chief Financial Officer) | Grant/Award | 240,000 240,000 held | $0.00 | 03/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PMVP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.3 % | 5.69 M | 4.25 M |
PMVP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PMVP ranks across every disease it competes in
Competitive Position is a premium feature
See how PMVP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPMVP News
PMVPPMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
PMV Pharmaceuticals has appointed Dr. Matt Eckler to its Board of Directors, bringing over 20 years of experience in healthcare investing and scientific research. The company is preparing to submit a New Drug Application for rezatapopt, aimed at treating platinum-resistant/refractory ovarian cancer. This drug has received Fast Track and Orphan Drug Designations from the FDA.
Read more →PMVPPMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
PMV Pharmaceuticals has appointed Philip Herman as Chief Commercial Officer to lead the launch preparation for rezatapopt, a therapy targeting platinum-resistant ovarian cancer. The company plans to submit a New Drug Application for accelerated approval in Q1 2027. Herman's extensive experience in oncology will support PMV's commercial strategy as they finalize clinical trials.
Read more →PMVP▲ +6.6%on this news
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
PMV Pharmaceuticals has announced the pricing of an oversubscribed public offering, which includes 22,055,000 shares of common stock and warrants to purchase an aggregate of 41,955,000 shares. The offering is expected to close on September 2, 2026, and aims to raise approximately $50.8 million. The securities are being sold under a shelf registration statement with the SEC.
Read more →PMVP▲ +6.6%on this newsshared move
PMV Pharma Announces Proposed Public Offering of Securities
PMV Pharmaceuticals has announced a proposed public offering of its common stock and accompanying warrants. The offering is being managed by TD Cowen and is subject to market conditions. PMV Pharma aims to raise capital to support its precision oncology initiatives targeting p53 mutations, which are prevalent in many cancers.
Read more →PMVP▲ +6.6%on this newsshared move
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
PMV Pharmaceuticals announced promising interim data from the PYNNACLE Phase 2 trial, showing a 46% overall response rate among 76 evaluable ovarian cancer patients. The median duration of response was reported at 10.0 months. The company plans to submit a New Drug Application for accelerated approval of rezatapopt in early 2027, following positive feedback from the FDA.
Read more →PMVPPMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
PMV Pharmaceuticals has successfully completed patient enrollment for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial focused on platinum-resistant/refractory ovarian cancer. The company plans to submit a New Drug Application (NDA) for Rezatapopt in the first quarter of 2027, indicating progress in their clinical development pipeline.
Read more →PMVPPMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
PMV Pharmaceuticals reported positive developments for rezatapopt, which received Orphan Drug Designation for treating TP53 Y220C positive ovarian cancer. The company plans to submit a New Drug Application for this indication in early 2027. Recent data published in the New England Journal of Medicine demonstrated the drug's potential effectiveness in advanced solid tumors. Financially, PMV ended Q1 2026 with $93.5 million in cash.
Read more →PMVPPMV Pharmaceuticals Announces Board Chair Transition
PMV Pharmaceuticals has announced a leadership transition on its Board of Directors, appointing Laurie Stelzer as the new Chair, effective June 4, 2026. Ms. Stelzer, who has over 25 years of experience in finance and business development, takes over from Dr. Rich Heyman, who will not stand for reelection. This leadership change comes as the company progresses with its ongoing PYNNACLE clinical trial evaluating rezatapopt for treating advanced solid tumors. PMV is also planning to submit a New Drug Application for rezatapopt in the first quarter of 2027.
Read more →PMVP▲ +7.2%on this news
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals announced its financial results for the year ending December 31, 2025, highlighting key developments in their clinical pipeline. The company is progressing with the Phase 2 PYNNACLE trial of rezatapopt for treating platinum-resistant ovarian cancer patients with a TP53 Y220C mutation. The FDA has granted orphan drug status to this candidate, which has demonstrated positive early results. However, the company reported a significant net loss and a decrease in cash reserves compared to the previous year.
Read more →PMVP▲ +22.3%on this news· ran to +52% by day 1
New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors
PMV Pharmaceuticals announced the publication of Phase 1 data for rezatapopt in the New England Journal of Medicine. The study involved 77 patients with advanced solid tumors and showed promising antitumor activity linked to the p53 Y220C mutation. The findings support the company's strategy for a Phase 2 trial and a future New Drug Application for ovarian cancer treatment.
Read more →PMVP▲ +6.8%on this news
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals reported its third quarter 2025 financial results, highlighting a cash position of $129.3 million. The company is advancing its PYNNACLE clinical trial for rezatapopt, a treatment targeting p53 mutations in ovarian cancer. CEO David Mack expressed optimism about submitting an NDA in early 2027. However, the company faces increasing operational costs.
Read more →PMVPPMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PMV Pharmaceuticals has announced updated interim data from the Phase 2 PYNNACLE trial, showcasing the efficacy of rezatapopt in patients with advanced solid tumors carrying the TP53 Y220C mutation. The results indicate significant clinical activity, particularly in platinum-resistant ovarian cancer. The company plans to submit a New Drug Application in early 2027, aiming to address the urgent need for better treatment options.
Read more →PMVP▲ +7.6%on this news
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
PMV Pharmaceuticals will present pivotal findings on rezatapopt at the AACR-NCI-EORTC conference. The oral presentation will focus on the initial analysis of the PYNNACLE Phase 2 trial for patients with advanced solid tumors harboring a TP53 Y220C mutation. Additionally, a poster will detail the natural history and prognostic value of this mutation in advanced tumors.
Read more →PMVP▼ -20.6%on this news
PYNNACLE Phase 2 Clinical Data Update
PMV Pharma provided an update on their investigational drug rezatapopt during an investor webinar. The Phase 2 PYNNACLE study has shown promising interim data, indicating efficacy and safety for treating patients with platinum-resistant ovarian cancer. The company plans to submit a New Drug Application (NDA) in Q1 2027 and asserts a solid financial position to support ongoing developments. However, the presentation also highlighted the inherent risks and uncertainties associated with clinical trials and regulatory approvals.
Read more →PMVP▼ -20.6%on this news
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PMV Pharmaceuticals has released promising interim data from its PYNNACLE Phase 2 clinical trial for rezatapopt, a drug targeting TP53 Y220C mutations. The trial showed a 33% overall response rate across various solid tumors, with a notable 43% in ovarian cancer. The company plans to submit a New Drug Application by early 2027. As part of its strategy, PMV Pharma aims to continue enrolling patients and will host a webinar to discuss the data and regulatory updates.
Read more →PMVPPMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights -PMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis data
PMV Pharmaceuticals has reported its financial results for the second quarter of 2025, including a cash position of $148.3 million, expected to last until late 2026. The company will host a webinar on September 10, 2025, to discuss interim analysis data from the Phase 2 PYNNACLE clinical trial involving 65 patients. The net loss increased to $21.2 million, and R&D expenses rose to $18.4 million due to higher costs in advancing their lead drug, rezatapopt, which has received Fast Track designation from the FDA.
Read more →PMVPPMV Pharmaceuticals to Participate at Upcoming Investor Conferences
PMV Pharmaceuticals will participate in upcoming investor conferences, including the TD Cowen 6th Annual Oncology Innovation Summit and the Jefferies Global Healthcare Conference. CEO David H. Mack and CDO Deepika Jalota will represent the company. The events will feature live audio webcasts, with replays available for 90 days.
Read more →PMVPPMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals reported its financial results for Q1 2025, highlighting continued progress in the clinical trial of rezatapopt, which is being evaluated for advanced solid tumors. The company has a cash balance of $165.8 million, projected to sustain operations through late 2026. Plans for an interim analysis from the ongoing Phase 2 PYNNACLE trial are set for mid-2025, which aims to evaluate the drug's effectiveness in a specific patient population. Despite these positives, the company reported a net loss increase and rising R&D expenses, raising concerns about operational costs and future results.
Read more →About PMV Pharmaceuticals, Inc.
Headquarters400 ALEXANDER PARK DRIVE, PRINCETON, NJ, 08540
BIOPHARMAWATCH ELITE PLUS
Trade the next PMVP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime